Genomics in Drug Discovery and DevelopmentEarly characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists. |
Contents
| 1 | |
2 Genomics Technologies as Tools in Drug Discovery | 25 |
3 Genomic Biomarkers | 105 |
4 Fundamental Principles of Toxicogenomics | 167 |
5 Toxicogenomics Applications to In Vivo Toxicology | 219 |
6 Toxicogenomics Applications in In Vitro Systems | 293 |
Other editions - View all
Common terms and phrases
activity allele amplification analysis approach array assays assessment associated biological breast cancer carcinogens cell lines Chapter chromosomal classify Clin clinical trials clustering compounds correlation data sets database detected diagnostic disease DNA methylation dose drug development drug discovery drug response effects efficacy end points enzyme evaluation function gefitinib gene copy gene copy number gene expression changes gene expression data gene expression profiles gene expression signatures genetic genome-wide genomic biomarkers genomic data genomic technologies genotyping hepatic hepatocytes hepatotoxicity high-throughput human hybridization identified induced irinotecan liver marker mechanisms mechanistic metabolism methylation microarray data microRNA miRNA molecular mRNA multiple mutations oligonucleotide pathways patients Pharmacogenetics Pharmacol phenotype polymorphisms potential preclinical predictive probes protein protocol rats regulatory relevant samples sensitivity sequence significant specific studies target therapeutic therapy tissue toxic changes toxicity toxicogenomics Toxicol toxicology transcriptional transcriptomic treatment troglitazone trovafloxacin tumors validation variability variants vitro vivo warfarin